Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health ...

The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol ...

Clearmind Medicine Inc. has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development of a proprietary alcohol substitute based on MEAI technology, utilizing Dr ...

Biotech company Clearmind Medicine (CMND) has received the approval of the Institutional Review Board for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder.

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec.

Clearmind Medicine Inc. Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech ...

Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal technology, a world-first ...

Clearmind is not responsible for the contents of third-party websites. 1 Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis, 2014.

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine ...